Myopia Outcome Study of Atropine in Children (MOSAIC): an investigator-led, double-masked, placebo-controlled, randomised clinical trial protocol [version 1; peer review: 2 approved, 1 approved with reservations] [PDF]
HRB Open Research, 2019 Background: The Myopia Outcome Study of Atropine in Children (MOSAIC) aims to explore the efficacy, safety, acceptability and mechanisms of action of 0.01% unpreserved atropine for myopia control in a European population.
Saoirse McCrann +8 more
doaj +3 more sources
Myopia Outcome Study of Atropine in Children (MOSAIC): an investigator-led, double-masked, placebo-controlled, randomised clinical trial protocol [version 2; peer review: 2 approved, 1 approved with reservations] [PDF]
HRB Open Research, 2019 Background: The Myopia Outcome Study of Atropine in Children (MOSAIC) aims to explore the efficacy, safety, acceptability and mechanisms of action of 0.01% unpreserved atropine for myopia control in a European population.
Saoirse McCrann +8 more
doaj +6 more sources
Recurrence of Acute Duodenal Ulcer [PDF]
Canadian Journal of Gastroenterology, 1994 Nizatidine, 300 mg once nightly, was compared with cimetidine, 800 mg once nightly, for treatment of 212 adult out-patients with acute duodenal ulcers in an eight-week randomized, double-blind, multicentre trial.
RJ Bailey +8 more
doaj +2 more sources
RESTORE: Once-nightly oxybate dosing preference and nocturnal experience with twice-nightly oxybates
Sleep Medicine: XObjective/Background: Preference for extended-release, once-nightly sodium oxybate (ON-SXB, FT218) vs twice-nightly immediate-release (IR) oxybate was assessed in participants switching from IR oxybate to ON-SXB in an open-label/switch study, RESTORE ...
Asim Roy +14 more
doaj +3 more sources
Efficacy of Topical 5% 5-Fluorouracil and 0.05% Tretinoin and Electrosurgery in the Treatment of Plane Warts: A Randomized Controlled Comparative Trial [PDF]
Nepal Journal of Dermatology, Venereology & Leprology, 2021 Human papilloma virus (HPV) is capable of causing varieties of dermatological conditions differing in morphology, histopathology and site of occurrence.
Rashmi Singh, Shyam Sundar Pandey
doaj +5 more sources
Journal of Comparative Effectiveness Research, 2023 What is this summary about? This is a plain language summary of a published article in the journal CNS Drugs. Narcolepsy is a rare sleep condition.
Thomas Roth +4 more
doaj +3 more sources
Journal of Comparative Effectiveness ResearchWhat is this summary about? This is a plain language summary of an article originally published in the journal Sleep Medicine. Narcolepsy is a sleep condition in which people have periods of extreme sleepiness during the day.
Richard Bogan +3 more
doaj +3 more sources
Pharmacokinetics of FT218, a Once-Nightly Sodium Oxybate Formulation in Healthy Adults [PDF]
Clinical Therapeutics, 2021 FT218 is an investigational, once-nightly, modified-release formulation of sodium oxybate (SO). SO effectively treats excessive daytime sleepiness and cataplexy in patients with narcolepsy. Current approved SO formulations, at effective doses of 6, 7.5, and 9 g, require twice-nightly divided dosing, with the first dose taken at bedtime and the second 2.
David, Seiden +2 more
openaire +4 more sources
0411 Once-Nightly Sodium Oxybate Dose Titration and Tolerability: Interim Data From RESTORE
Sleep, 2022 Abstract Introduction Extended-release, once-nightly sodium oxybate (ON-SXB; FT218) is under FDA review for the treatment of adults with narcolepsy. RESTORE, an ongoing, open-label extension/switch study (NCT04451668), evaluates long-term ON-SXB safety and tolerability.
Asim Roy +6 more
+5 more sources
Neurology and Therapy, 2023 Narcolepsy is associated with disrupted nighttime sleep (DNS). Sodium oxybate (SXB; Xyrem®), administered twice nightly, is indicated for the treatment of cataplexy and excessive daytime sleepiness in patients 7 years or older with narcolepsy.
Russell Rosenberg +5 more
doaj +1 more source